San Diego-dependent Viking Therapeutics marked itself as a serious competitor during the weight loss drug sector in February soon after revealing promising information from the mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection and in March the compan